On Saturday 2 June 2018, Synthon will present new and updated data from the Phase I clinical study with [vic-]trastuzumab duocarmazine (also known as SYD985).
The data demonstrate that this anti- HER2 antibody-drug conjugate (ADC) shows promising efficacy in heavily pretreated patients with HER2-positive and HER2-low breast cancer. Earlier this year, the U.S. FDA granted Fast Track designation for this novel ADC, and a Phase III study (TULIP®) with this drug candidate is currently ongoing in patients with HER2-positive breast cancer.
The corresponding abstract #1014 can be found here (poster board #95). For more information on [vic-]trastuzumab duocarmazine, click here.